By Christian Kuttruff and Julien Lefranc The first disclosures of new drug candidates are always the highlight of medicinal chemistry conferences. Six novel drug candidates were recently disclosed by European companies at the European Federation for Medicinal Chemistry International Symposium …
Recently, our team at Drug Hunter compiled the lead programs and mechanisms of small molecule and large molecule biotechs that IPO’d in 2020. We asked featured reviewers from our community what stood out to them about the science of this …
Thanks to our featured reviewers for their feedback, with special thanks to neuroscience reviewer Jake Schwarz for feedback and commentary on an unusual 5 neuroscience molecules this month. July’s edition of Small Molecules of the Month, features a selective monovalent …
Looking at the pipelines of recent biotech IPOs is a great way to get a snapshot of new technologies and approaches to drug discovery or to see what’s coming in smaller indications. Complementing our recent highlight of large molecule-focused companies, …
Browsing through the pipelines of recent biotech IPOs is great way to catch up on emerging targets, novel drug modalities, and science at the edge of development. Unlike conferences and publications which tend to be a lagging indicator of what’s …
June’s edition of Small Molecules of the Month features a natural product-derived RNA splicing modulator, a mTORC1-selective “bi-steric” inhibitor, numerous low-dose clinical candidates and several unusual chemical motfs (e.g. pyridine N-oxide, sulfinylamine, boronic acid). Links to articles, PDF download, and …